AU1227899A - Osmotic medicament releasing system - Google Patents

Osmotic medicament releasing system

Info

Publication number
AU1227899A
AU1227899A AU12278/99A AU1227899A AU1227899A AU 1227899 A AU1227899 A AU 1227899A AU 12278/99 A AU12278/99 A AU 12278/99A AU 1227899 A AU1227899 A AU 1227899A AU 1227899 A AU1227899 A AU 1227899A
Authority
AU
Australia
Prior art keywords
osmotic
releasing system
release system
drug release
medicament releasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12278/99A
Other languages
English (en)
Inventor
Patrick Bosche
Erich Brendel
Ernst Chantraine
Michael Eisele
Ranga-Rao Kanikanti
Stefan Kettelhoit
Claus Weisemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU1227899A publication Critical patent/AU1227899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AU12278/99A 1997-10-25 1998-10-12 Osmotic medicament releasing system Abandoned AU1227899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19747261 1997-10-25
DE19747261A DE19747261A1 (de) 1997-10-25 1997-10-25 Osmotisches Arzneimittelfreisetzungssystem
PCT/EP1998/006454 WO1999021535A1 (de) 1997-10-25 1998-10-12 Osmotisches arzneimittelfreisetzungssystem

Publications (1)

Publication Number Publication Date
AU1227899A true AU1227899A (en) 1999-05-17

Family

ID=7846661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12278/99A Abandoned AU1227899A (en) 1997-10-25 1998-10-12 Osmotic medicament releasing system

Country Status (9)

Country Link
US (1) US6294201B1 (cg-RX-API-DMAC10.html)
EP (1) EP1024793B1 (cg-RX-API-DMAC10.html)
JP (1) JP4295916B2 (cg-RX-API-DMAC10.html)
AT (1) ATE211907T1 (cg-RX-API-DMAC10.html)
AU (1) AU1227899A (cg-RX-API-DMAC10.html)
CA (1) CA2307018C (cg-RX-API-DMAC10.html)
DE (2) DE19747261A1 (cg-RX-API-DMAC10.html)
ES (1) ES2172239T3 (cg-RX-API-DMAC10.html)
WO (1) WO1999021535A1 (cg-RX-API-DMAC10.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
PT1424997E (pt) * 2001-09-14 2008-02-28 Scolr Inc Forma de dosagem de libertação prolongada modulada por aminoácidos
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
SK286107B6 (sk) * 2002-04-12 2008-03-05 Zentiva, A. S. Analgeticky účinný perorálny liečivý prípravok s kontrolovaným uvoľňovaním opioidnej účinnej látky a spôsob jeho prípravy
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
WO2006116247A1 (en) * 2005-04-25 2006-11-02 Teva Pharmaceuticals Usa, Inc. Extended release formulations
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
WO2007039132A1 (de) 2005-10-04 2007-04-12 Bayer Healthcare Ag Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013167453A1 (en) 2012-05-07 2013-11-14 Bayer Pharma Aktiengesellschaft Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
TW202019402A (zh) * 2018-07-24 2020-06-01 德商拜耳廠股份有限公司 可口服之修飾釋放藥物劑型
US20210283046A1 (en) * 2018-07-24 2021-09-16 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
PH12022553407A1 (en) 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU466503B2 (en) * 1972-06-05 1975-10-30 Alza Corporation Osmotic dispenser
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
DE19515972A1 (de) 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway

Also Published As

Publication number Publication date
ATE211907T1 (de) 2002-02-15
ES2172239T3 (es) 2002-09-16
DE19747261A1 (de) 1999-04-29
CA2307018A1 (en) 1999-05-06
US6294201B1 (en) 2001-09-25
JP2001520985A (ja) 2001-11-06
CA2307018C (en) 2006-12-12
DE59802670D1 (de) 2002-02-21
EP1024793B1 (de) 2002-01-16
EP1024793A1 (de) 2000-08-09
WO1999021535A1 (de) 1999-05-06
JP4295916B2 (ja) 2009-07-15

Similar Documents

Publication Publication Date Title
CA2307018A1 (en) Osmotic medicament releasing system
NO992907D0 (no) Flat legemiddeltilberedning for applikasjon og frigiving av buprenorfin eller et annet farmakologisk sammenlignbart stoff i munnhulen og fremgangsmÕte for dens fremstilling
IE871584L (en) Sustained release capsule.
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
UA41995C2 (uk) Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
CA2386690A1 (en) Pharmaceutical tramadol salts
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
HUP0003121A3 (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
AU5084299A (en) Sustained release pharmaceutical preparation
YU36700A (sh) Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
CA2136411A1 (en) Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating
CA2152062A1 (en) Enhanced Solubility Pharmaceutical Solutions
ATE260645T1 (de) Agitationsunabhängige pharmazeutische multiple- unit-retardzubereitungen und verfahren zu ihrer herstellung
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
EA199900734A1 (ru) Микрокапсулы, содержащие цис-платину
IL150528A0 (en) Ibuprofen containing active agent preparation
BG108516A (en) Pharmaceutical formulation
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase